Sign in
Taking people in United StatesPhase 2

Immunosuppressant Timing Before Elective Shoulder Replacement in Rheumatology Patients

Compares stopping immunosuppressant drugs for longer versus shorter periods before shoulder replacement in rheumatic disease.

Key facts

Who runs it
NYU Langone Health
Where
New York, United StatesSee the site
Trial code
Registry title
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Status
Recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
12 Dec 2025
Expected to end
Jan 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Methotrexate
  • Sulfasalazine
  • Hydroxychloroquine
  • Leflunomide
  • Azathioprine
  • Mycophenolate
  • Cyclosporine
  • Tacrolimus
  • Etanercept
  • Adalimumab
  • Golimumab
  • Certolizumab
  • Infliximab
  • Rituximab
  • Belimumab
  • Tocilizumab
  • Anakinra
  • Canakinumab
  • Abatacept
  • Secukinumab
  • Ixekizumab
  • Bimekizumab
  • Ustekinumab
  • Guselkumab
  • Risankizumab
  • Tofacitinib
  • Upadacitinib
Record updated
9 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a rheumatic disease who take immunosuppressant medicine and are scheduled for an elective total shoulder replacement.

Age
18 years and older
Sex
All sexes can join.
Disease stage
A rheumatic disease such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lupus, juvenile idiopathic arthritis, polymyalgia rheumatica, giant cell arteritis or vasculitis.
Earlier treatment
Must have been on active immunosuppression for at least 3 months before the planned surgery.

Main reasons for not taking part

  • Active infection or cancer
  • Shoulder replacement because of a fracture or tumor
  • Pregnancy or breastfeeding
  • Severe lupus with marked disease activity
  • Cannot give written informed consent

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adults aged 18 years and older at the time of informed consent
  • Diagnosis of rheumatic disease: rheumatoid arthritis (RA), psoriatic arthritis (PA) , ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), spondyloarthritis, polymyalgia rheumatica, giant cell arteritis, vasculitis, granulomatosis with polyangiitis, dermatomyositis, polymyositis, and inflammatory bowel disease-associated arthritis
  • On active immunosuppression for at least 3 months prior to scheduled surgery
  • Scheduled for elective total shoulder arthroplasty
  • Able and willing to provide written informed consent prior to any study specific procedures

Who cannot take part

  • Unable or without capacity to provide written informed consent prior to any study specific procedures
  • Patients with active infections or malignancies
  • Patients with severe SLE with marked activity - as they should be offered enrollment in the observational arm. All such patients should remain on treatment to avoid worsening of disease activity
  • Patients undergoing shoulder arthroplasty for fracture or tumor
  • Pregnancy or breastfeeding
  • Unable to provide informed consent

Where in United States

  • NYU Langone HealthNew York, United StatesContact: Thomas ChalothronTaking people

About the trial

What the trial wants to find out

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

The 2 groups in the trial

  • Standard holdExisting treatment, for comparison

    Patients will follow the standard perioperative immunosuppressant hold protocol based on guidelines from hip and knee arthroplasty literature. The duration of the hold is determined by medication half-life and infection risk considerations. Postoperatively, medications will be restarted approximately 2 weeks after surgery (+/- 2 days), contingent on wound healing and infection status.

    Treatment: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, and Secukinumab

  • Shorter holdTreatment being tested

    Patients will follow an abbreviated immunosuppressant hold protocol, withhold durations modified based on drug pharmacokinetics to allow a shorter preoperative discontinuation period. Medications will be prescribed as usual by the patient's rheumatologist, only adjusting the interval between last preoperative dose and surgery. The rheumatologist will relay the number of weeks/days between the last dose and surgery date. Postoperatively, medications will be restarted approximately 1 week after surgery (+/- 2 days), provided there are no signs of infection or wound healing complications. Route of Administration

    Treatment: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, and Secukinumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Plain-language title
Immunosuppressant Timing Before Elective Shoulder Replacement in Rheumatology PatientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 July 2026